Most Read Articles
11 Aug 2019
Intraoperative methylprednisolone does not appear to significantly prevent the incidence of death, cardiac arrest and other injuries in neonates undergoing cardiac surgery with cardiopulmonary bypass, according to a recent study.
11 Aug 2019
Treatment with low-to-standard dose dual combination therapy of blood pressure (BP)-lowering drugs is more effective than standard-dose monotherapy and does not increase withdrawals due to adverse events, a recent study has shown.
20 Jun 2019
Untreated white coat hypertension (WCH), but not treated white coat effect (WCE), may increase the risk for cardiovascular events and all-cause mortality, suggest the results of a systematic review and meta-analysis. Out-of-office blood pressure (BP) monitoring is thus important in the diagnosis and management of hypertension.
06 Aug 2019
Risk factors for 1-year mortality in heart failure (HF) patients significantly differ between those with and without chronic kidney disease (CKD), especially with regard to the use of beta-blockers or diuretics at discharge, according to a study. This suggests that these patients may benefit from individualized therapies.

Predictors of adverse outcomes in medically treated valvular heart disease patients

Stephen Padilla
28 May 2019
A new synthetic heart has valves, arteries and veins made of polyvinyl alcohol hydrogel

New York Heart Association (NYHA) functional class III, multiple valve involvement and right ventricular area change predict the incidence of adverse outcomes among medically treated patients with valvular heart disease (VHD), according to a new study presented at the Asian Pacific Society of Cardiology (APSC) 2019 Congress held at the SMX Convention Center in Manila, Philippines.

These adverse outcomes include unscheduled emergency department visit, unscheduled admission, acute decompensated heart failure and mortality, according to study authors Ma. Criselda Nuevo-Ramirez, MD, and Jose Melanio Grayda, MD, both from the Philippine Heart Center.

A total of 246 patients were analysed in the study, of which 36 (14 percent) were noted to have had adverse outcomes. Among the clinical parameters, NYHA functional class III (odds ratio [OR], 6.4; p=0.027) was associated with an increased risk of adverse outcome. [APSC 2019, poster 04]

In terms of echocardiographic parameters, the risk of adverse outcomes was influenced by multiple valve involvement compared with isolated mitral valve disease (mitral and aortic: OR, 12.5; p=0.023; mitral and tricuspid: OR, 9.3; p=0.033; mitral, aortic and tricuspid: OR, 9.7; p=0.032) as well as right ventricular fractional area change (OR, 0.97; p=0.046).

“Only a few contemporary studies enabled spontaneous prognosis to be assessed according to patient characteristics,” the researchers said. “Operative mortality was noted to be predicted using the Euroscore II. However, no scoring system enabled the spontaneous outcome to be assessed for nonoperative mortality and other adverse outcomes.” [Eur Heart J 2007;28:230-268]

Nuevo-Ramirez and Grayda also suggested that recognizing patients at high risk for adverse outcomes might help healthcare providers in deciding which patient would benefit from more aggressive monitoring or earlier intervention.

This prospective cohort study included VHD patients seen at the outpatient department (OPD) and used the OPD logbook for 2014–2017 to identify those that were eligible for inclusion. The researchers interviewed the patients and reviewed charts to obtain clinical, echocardiographic and laboratory data. Follow-up period was 6 months. Composite outcomes were used.

For the study duration, the researchers conducted interval follow-up for outcome monitoring through OPD chart review, phone call or by interview on their next OPD visit. Clinical characteristics of patients were summarized using descriptive statistics. ORs from binary logistic regression were estimated to determine significant predictors for mortality. Missing variables were neither replaced nor estimated.

Nuevo-Ramirez and Grayda said that a larger population and a longer follow-up period are warranted to help identify other predictors of adverse outcomes among medically treated adult VHD patients.

“Evaluation of the prognosis of VHD is derived from studies on natural history, which are frequently old and not always applicable to current presentations,” they noted. [Eur Heart J 2007;28:230-268]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
11 Aug 2019
Intraoperative methylprednisolone does not appear to significantly prevent the incidence of death, cardiac arrest and other injuries in neonates undergoing cardiac surgery with cardiopulmonary bypass, according to a recent study.
11 Aug 2019
Treatment with low-to-standard dose dual combination therapy of blood pressure (BP)-lowering drugs is more effective than standard-dose monotherapy and does not increase withdrawals due to adverse events, a recent study has shown.
20 Jun 2019
Untreated white coat hypertension (WCH), but not treated white coat effect (WCE), may increase the risk for cardiovascular events and all-cause mortality, suggest the results of a systematic review and meta-analysis. Out-of-office blood pressure (BP) monitoring is thus important in the diagnosis and management of hypertension.
06 Aug 2019
Risk factors for 1-year mortality in heart failure (HF) patients significantly differ between those with and without chronic kidney disease (CKD), especially with regard to the use of beta-blockers or diuretics at discharge, according to a study. This suggests that these patients may benefit from individualized therapies.